Endometrium - Large Biopsy 3-6 cm

Biopsy

Report in 288Hrs

At Home

No Fasting Required

Details

Histopathology of uterine lining & fibroids.

₹666₹951

30% OFF

Endometrium - Large Biopsy 3-6 cm: Comprehensive Medical Test Guide

Why is it done?
- Tissue sampling and histopathological examination: This procedure involves obtaining a large tissue sample (3-6 cm) from the endometrium (uterine lining) for detailed microscopic evaluation to detect abnormal cell growth and pathological changes
- Detection of endometrial cancer or precancerous lesions (endometrial hyperplasia and atypical hyperplasia)
- Evaluation of abnormal uterine bleeding or postmenopausal bleeding to exclude malignancy
- Assessment of thickened endometrium on ultrasound imaging (typically >4 mm in postmenopausal women or >16 mm in premenopausal women)
- Diagnosis of chronic endometritis or other inflammatory conditions of the endometrium
- Investigation of infertility or recurrent miscarriages when endometrial pathology is suspected
- Monitoring of tamoxifen therapy side effects in breast cancer patients
- Typically performed when smaller biopsies are inconclusive, insufficient tissue sample is obtained, or when extensive sampling is required for comprehensive pathological assessment
Normal Range
- Normal findings: Benign endometrial tissue with normal glandular architecture, appropriate secretory or proliferative changes based on menstrual cycle phase, and absence of malignancy or significant inflammation
- Normal endometrial thickness: Generally less than 4 mm in postmenopausal women and 8-16 mm in premenopausal women during the proliferative phase (may be thicker during secretory phase)
- Negative for malignancy: No evidence of endometrial cancer or atypical cells present
- Specimen quality: Adequate tissue sample with sufficient endometrial tissue for complete pathological examination (large biopsy 3-6 cm provides extensive material)
- Units of measurement: Tissue dimensions in centimeters, microscopic findings described in standard histopathological terminology
- Interpretation categories: Benign (normal), benign with atypia, hyperplasia (simple or complex, with or without atypia), malignancy, or insufficient material
Interpretation
- Benign/Normal findings: Indicates healthy endometrial tissue with appropriate morphology for patient age and cycle phase; no intervention required; reassurance regarding absence of malignancy
- Simple hyperplasia without atypia: Increased glandular proliferation with low malignant potential (less than 1% risk of progression to cancer); may recommend progestin therapy or hormonal management; follow-up imaging or biopsy may be considered
- Complex hyperplasia without atypia: More crowded glandular architecture without cytologic atypia; intermediate risk (approximately 3-5% malignant progression risk); generally managed with progestin therapy; close clinical follow-up recommended
- Atypical hyperplasia/Endometrial intraepithelial neoplasia (EIN): Cytologic atypia present with glandular crowding; precancerous lesion with 20-30% risk of concurrent or future endometrial cancer; typically warrants hysterectomy or aggressive progestin therapy with close surveillance; requires multidisciplinary discussion of treatment options
- Endometrial cancer (adenocarcinoma): Malignant tissue present; requires immediate referral to gynecologic oncology; staging studies (imaging, possible lymph node assessment) needed; treatment typically involves hysterectomy, salpingo-oophorectomy, and possible chemotherapy/radiation based on tumor grade and stage
- Chronic endometritis: Inflammatory infiltrate present (lymphocytes and plasma cells); may be associated with abnormal bleeding or infertility; management may include antibiotics or anti-inflammatory therapy; identify underlying cause (infection, retained products of conception, IUD-related)
- Factors affecting interpretation: Menstrual cycle phase at time of biopsy affects normal morphology; estrogen and progestin exposure; hormone replacement therapy use; tamoxifen or other endocrine medications; prior endometrial procedures; quality and extent of tissue sample obtained
- Clinical significance: Large endometrial biopsies provide extensive tissue for comprehensive pathological assessment; superior diagnostic accuracy compared to smaller biopsies; allows accurate grading and staging of malignancies; enables detection of focal lesions and heterogeneous pathology; critical for treatment planning in endometrial cancer
Associated Organs
- Primary organ system: Reproductive system (uterus and endometrium specifically); secondary involvement of ovaries (estrogen production), pituitary gland (gonadotropins), and hypothalamus (hormone regulation)
- Medical conditions associated with abnormal results: Endometrial adenocarcinoma (Type I and II), endometrial hyperplasia, atypical hyperplasia, chronic endometritis, endometriosis, adenomyosis, uterine polyps, endometrial fibroids, endometrial sarcoma, carcinosarcoma (malignant mixed müllerian tumor), and metastatic cancers involving the endometrium
- Diseases this test helps diagnose: Endometrial cancer (most important); endometrial hyperplasia and its atypical variants; chronic infection or inflammation; unexplained abnormal uterine bleeding; postmenopausal bleeding etiology determination; malignancy related to tamoxifen therapy; Lynch syndrome-related cancers; endometrial involvement in systemic diseases
- Risk factors for abnormal results: Obesity (chronic estrogen exposure from peripheral aromatization); diabetes mellitus; hypertension; nulliparity (no pregnancies); age over 50; estrogen replacement therapy without progestin; tamoxifen use; metabolic syndrome; polycystic ovary syndrome (PCOS); family history of endometrial or colorectal cancer
- Potential complications or risks: Uterine perforation (rare, 1-2 per 1000 procedures); excessive vaginal bleeding or cramping; infection (endometritis); anesthesia-related complications; damage to fallopian tubes; psychological impact of cancer diagnosis; need for major surgery (hysterectomy) if malignancy confirmed
Follow-up Tests
- If endometrial cancer is diagnosed: Abdominal and pelvic CT or MRI imaging for staging; chest CT or X-ray to exclude pulmonary metastases; tumor molecular testing (microsatellite instability, mismatch repair deficiency status); CA-125 blood test; possible PET/CT in select cases; referral to gynecologic oncology for surgical staging and treatment planning
- If atypical hyperplasia is found: Pelvic ultrasound for endometrial thickness reassessment; possible MRI for detailed uterine evaluation; consideration for repeat biopsy or hysterectomy; endometrial ablation if conservative therapy chosen; close follow-up biopsies if managed medically
- If endometrial hyperplasia (non-atypical) is detected: Pelvic ultrasound in 3 months to assess endometrial response; repeat endometrial biopsy in 6-12 months to confirm regression with hormonal therapy; blood glucose and lipid panel if not recently obtained; assessment of estrogen exposure sources
- If chronic endometritis is diagnosed: Endometrial cultures or molecular testing for infectious organisms if indicated; pelvic ultrasound to exclude retained products of conception; investigation for IUD-related infection if present; repeat biopsy after antibiotic therapy to confirm resolution
- If normal findings in abnormal bleeding context: Consider additional imaging (saline infusion sonography) to evaluate for polyps or fibroid; assessment for coagulation disorders; evaluation for anovulation or hormonal abnormalities; gynecologic evaluation for other causes of abnormal bleeding
- Monitoring and surveillance: Post-cancer treatment surveillance imaging every 6-12 months for first 2 years; annual pelvic ultrasound for hyperplasia management; clinical follow-up appointments at regular intervals; surveillance for recurrent symptoms or abnormal bleeding
- Related complementary tests: Pap smear (cervical cancer screening); HPV testing; transvaginal ultrasound; hysteroscopy with directed biopsy; endometrial curettage; molecular pathology studies (estrogen/progesterone receptor status); immunohistochemistry for specific tumor markers
Fasting Required?
- Fasting requirement: No fasting required for this biopsy procedure
- Timing considerations: Procedure typically scheduled during follicular phase (days 7-14) of menstrual cycle when possible (thinner endometrium); avoid scheduling during heavy menstrual flow or pregnancy; preferably performed not during menstruation
- Medications to avoid: Anticoagulants (warfarin, apixaban, rivaroxaban) - discontinue 3-5 days prior if possible or as directed by prescribing physician; aspirin and NSAIDs - stop 1 week before procedure if possible; antiplatelet agents may be continued per cardiologist recommendation; hormone replacement therapy - typically continued; contact prescribing physician before stopping any medications
- Anesthesia requirements: If general anesthesia planned: NPO (nothing by mouth) for 6-8 hours prior; specify if receiving general anesthesia during office visit; local anesthesia only requires no fasting
- Pre-procedure requirements: Pregnancy test (urine or serum hCG) if reproductive age and menses status uncertain; signed informed consent documenting understanding of risks and benefits; history and physical examination; assessment of bleeding risk; pelvic examination prior to procedure; void bladder immediately before procedure; comfortable clothing worn (preferably allowing easy access)
- Post-procedure instructions: Resume regular diet and medications after procedure; mild cramping and vaginal bleeding normal for 1-2 days; use sanitary pads, not tampons for 1 week; avoid intercourse and douching for 1 week; avoid strenuous exercise for 48 hours; contact physician if heavy bleeding, fever, severe abdominal pain, or signs of infection develop; report results typically available in 7-10 business days
- Special considerations: Arrange transportation if receiving sedation; bring photo ID and insurance card; notify facility of active infections or immunosuppression; inform team of severe cervical stenosis or uterine anomalies that may affect procedure; cervical dilation may be necessary prior to large biopsy

How our test process works!